Sign in3 stories
Celldex reported that EMBARQ-CSU1 and EMBARQ-CSU2 met their primary endpoint and all key secondary endpoints at 12 weeks, with a BLA submission planned for 2027.
SEC filing
Celldex says its two pivotal CSU trials completed enrollment ahead of schedule, with topline results due in September or October 2026 ahead of a planned 2027 BLA filing.
SEC filing
Celldex Therapeutics disclosed that Chief Financial Officer Sam Martin plans to retire effective on or about March 31, 2027, with a search underway for his successor.
SEC filing